![]() |
市場調查報告書
商品編碼
1677736
偏頭痛的全球市場 (~2032年):類型·治療類型·藥物類別·各地區Global Migraine Market Research Report Information by Type, By Treatment Type, By Drug Class, And by Region Market Forecast Till 2032 |
全球偏頭痛市場規模預計將從 2023 年的 56.8 億美元和 2024 年的 60 億美元增長到 2032 年的 84.2 億美元,預測期內的複合年增長率為 3.83%。
社會對新型藥物認知的提高和全球偏頭痛發生率的增加是影響該市場成長的兩個主要因素。降鈣素基因相關勝肽 (CGRP) 的引入預計也將推動成長。偏頭痛是一種複發性劇烈頭痛,伴隨畏光、畏聲和噁心。遺傳因素在疾病的發展中扮演一定的角色。失望、緊張、焦慮、震驚和興奮等不平衡的情緒會引發偏頭痛。偏頭痛發作的持續時間和強度各不相同,並且經常影響頭部的一側。偏頭痛發病頻率的增加、大量未滿足的醫療需求、由於研發支出的增加而不斷增長的藥物管道以及對偏頭痛和可用治療方法的了解不斷加深,也促進了該市場的成長。
區域展望
預計亞太市場在整個研究期間將見證顯著的複合年增長率。隨著中國和印度等新興國家的醫療成本上升和基礎設施改善,亞太市場預計將擴大。由於監管機構不斷擴大舉措,以合理的價格輕鬆獲得偏頭痛治療選擇也是推動該區域市場發展的關鍵因素。
歐洲佔第二大市場。推動該市場成長的兩個主要因素是世界範圍內偏頭痛問題的日益嚴重以及公眾對新型藥物認識的不斷提高。此外,降鈣素基因相關勝肽(CGRP)的推出也有望支持這一增長。
預計北美市場將在 2024 年至 2032 年期間以最高的複合年增長率成長。預計當地市場將受益於美國、加拿大和其他國家正在進行的大量研究和開發活動,以尋找新的治療方案。
本報告提供全球偏頭痛的市場調查,彙整市場定義和概要,市場成長的各種影響因素分析,市場規模的轉變·預測,各種區分·地區/各主要國家的明細,競爭環境,主要企業簡介等資訊。
Global Migraine Market Research Report Information by Type (Episodic and Chronic), By Treatment Type (Preventive, Abortive), By Drug Class (Triptans, Ergots, and Others), And by Region (North America, Europe, Asia-Pacific, And Rest of The World) Market Forecast Till 2032
In 2023, the migraine market was estimated to be worth USD 5.68 billion. The global migraine market is expected to expand at a compound annual growth rate (CAGR) of 3.83% from 2024 to 2032, from USD 6.00 billion in 2024 to USD 8.42 billion.
The two main factors propelling market expansion are the rise in migraine issues worldwide and the growing public knowledge of new medication classes.
Growing public awareness of new drug classes and a rise in migraine problems globally are two factors influencing the target market's growth. It is also anticipated that the introduction of calcitonin gene-related peptide (CGRP) will facilitate the growth of this enterprise. Migraine is a recurrent, severe headache that is accompanied by photophobia, phonophobia, and nausea. Genes play a role in the development of illness. Out-of-balance emotions, including dejection, tension, anxiety, shock, and excitement, can cause migraine headaches. Each migraine attack varies in length and intensity and often affects one side of the head. Factors include an increase in migraine frequency with substantial unmet needs, rising R&D expenditures resulting in a sizable drug pipeline, and an increase in our understanding of migraine and available treatments.
Perspectives on Market Segments
The migraine market is divided into two divisions based on type: episodic and chronic.
The migraine market is divided into two segments based on the kind of treatment: preventive and abortive.
Surgery has divided the market data into three categories: triptans, ergots, and others.
Regional Perspectives on Migraines
The analysis offers market insights by region, including Asia-Pacific, Europe, North America, and the rest of the world. Throughout the study period, a notable compound annual growth rate (CAGR) is anticipated in the Asia Pacific migraine market. As healthcare expenses rise and infrastructure in emerging countries like China and India improves, the Asia Pacific acute migraine treatment market is predicted to grow in size. The easy availability of reasonably priced migraine treatment choices backed by growing regulatory body initiatives is another significant aspect that is probably propelling the regional market. by the Brand Equity Foundation of India.
The second largest market share is held by the migraine industry in Europe. Two reasons driving the target market's growth are the rise in migraine issues worldwide and the growing public knowledge of new medicine classes. Furthermore, the launch of calcitonin gene-related peptide (CGRP) is expected to support the growth of this sector.
From 2024 to 2032, the North American migraine market is anticipated to expand at the quickest compound annual growth rate. increasing financial contributions from powerful U.S.-based parties. The local market is expected to gain from the substantial research and development activities conducted in the US, Canada, and other nations to identify novel treatment choices. According to the American Family Physician, there are approximately 441.5 million adults in the United States, of whom 6-9% are men and 18-26% are women. In 2009, the United States suffered a migraine.
Among the leading companies in the migraine market are Johnson & Johnson, Endo International Plc, GlaxoSmithKline Plc, Abbott Laboratories, Teva Pharmaceutical Industries Limited, Allergan Plc, Pfizer Inc., AstraZeneca, and Impax Laboratories.